Investor RelationsPress center
  1. Home
  2. Laboratory Diagnostics
  3. Assays by Diseases and Conditions
  4. Cardiac Assays
  5. High-Sensitivity Troponin I Assays
TNIH key visual

High-Sensitivity Troponin I Assay

Fast, Accurate, Actionable Results When it Matters Most

Atellica IM High-Sensitivity Troponin I Assay is First in the U.S. to Include Prognostic Risk

Siemens Healthineers High-Sensitivity Troponin I (TnIH) can be used to aid in offering rapid and accurate detection of AMI helping lead to a faster diagnosisA and now also assists clinicians to help identify future cardiovascular event risk based on the new FDA-cleared prognostic risk claim extension

TnIH Icons with Checkmark

Assist with the creation of tailored care plans

Prognostic risk metrics for Major Adverse Cardiac Events at 30-, 90-, 182-, and 365-days post-ED visitB

TnIH Icon with progress icon

Aids in rapidly and accurately detecting AMI​

Highly precise results across over 90% of the low end of detection

RiskIcons

STAT results without interrupting routine workflows​

10-minute STAT results without interrupting routine workflows

Proven, True High-Sensitivity Troponin I Assays

Designed to aid in diagnosing acute myocardial infarctions (AMI) through the quantitative measurement of cardiac troponin I in serum or plasma, high-sensitivity troponin plays a critical role in the timely diagnosis of AMI, or heart attacks.

Siemens Healthineers offers proven, true high-sensitivity cardiac troponin I assays:

  • Demonstrate clinical proof that the Siemens Healthineers’ assays are true high-sensitivity troponin I assays according to current guidelines.1-4
  • Offer fast, accurate, and actionable results to leverage current protocols
  • Provide confidence in results due to minimal assay interferences, including biotin*

 

Atellica Solution high-sensitivity troponin I results in 10 minutes

The Atellica® Solution’s streamlined STAT process has been shown to deliver actionable high-sensitivity troponin I results in 10 minutes.

Trusted Results Across Systems

Siemens Healthineers is proud to offer high-sensitivity troponin I across multiple systems, including the Atellica® IM Analyzer, ADVIA Centaur® System, Dimension® EXL™ Integrated Systems, and Dimension Vista® Intelligent Lab Systems.

All Siemens Healthineers High-Sensitivity Troponin I Assays meet the ESC and AACC Academy/IFCC C-CB guidelines for high-sensitivity troponin assays1

How Precise is Your Troponin?

Sensitivity and precision at the low end of the measuring range provides the ability to measure slight, yet critical, changes between serial troponin I values

1/3
troponin graph and detection
1/3

Recent Studies Demonstrate Performance of High-sensitivity Troponin I Assay

Over the past 20 years the analytical sensitivity and precision of cardiac troponin (cTn) assays have improved for very low cTn concentrations. Compared to traditional cTn assays, high-sensitivity troponin I (hs-cTnI) assays can detect lower levels of troponin and smaller changes to a patient’s troponin levels, which may be an early indication of AMI.

A new literature compendium features recent articles offering guidance on the use of hs-cTnI assays, with respect to assay type (POC vs. central lab), sex-specific cutoffs, serial testing, single-test rule-out, and reporting units.

These studies show that the Siemens Healthineers high-sensitivity troponin I assays are proven, true high-sensitivity cardiac troponin I assays that provide fast, accurate, and actionable test results.

See the results of these studies and the realized benefits to patients and hospitals.

Outpatient Versus Observation/Inpatient Management of Emergency Department Patients Rapidly Ruled-out for Acute Myocardial Infarction: Findings from the HIGH-US Study5

A recent study described the clinical characteristics of acute myocardial infarction (AMI) ruled-out patients placed in observation/inpatient beds (OBS/ADM) vs. those with an ED discharge (EDD) using the HIGH-US 0/1 hour (h) study algorithm, and the cardiac testing and interventions that were completed in the group placed in OBS/ADM.

For patients at very low risk for AMI within 30 days, those with a history of coronary artery disease (CAD), stroke, hypertension, or having an abnormal ECG, or a family history of CAD were more likely placed in OBS/ADM than EDD. Decisions to admit or place patients in observation could be reduced based on the prognosis for these patients and the 0/1 h rapid algorithm. This would lead to shorter lengths of hospital stay and fewer patients receiving further unnecessary cardiac procedures.

The observational findings from the HIGH-US multicenter study suggest that most patients presenting to the ED with symptoms suspicious for AMI but meeting the rapid rule-out AMI criteria using a hs-cTnI 0/1-hour algorithm might be managed as outpatients.

1

Apple F., Sandoval Y., Jaffe A., and Ordonez-Llanos J. Cardiac Troponin Assays: Guide to Understanding Analytical Characteristics and Their

Impact on Clinical Care. Report of the IFCC Task Force on Clinical Applications of Cardiac Biomarkers. Clinical Chemistry 63:01 (2016)

2

Alan H.B. Wu, Clinical Chemistry 64:4 645–655 (2018)

3

European Heart Journal 2020 00, 179 ESC GUIDELINESdoi:10.1093/eurheartj/ehaa575

4

European Heart Journal 2020 00, 179 ESC GUIDELINESdoi:10.1093/eurheartj/ehaa575

5

Nowak, et al. Outpatient Versus Observation/Inpatient Management of Emergency Department Patients Rapidly Ruled-out for Acute

Myocardial Infarction: Findings from the HIGH-US Study. American Heart Journal 2020 Oct 27. DOI: 10.1016/j.ahj.2020.10.067

*Atellica IM TnIH & ADVIA Centaur TNIH assays: Biotin interference demonstrating less than 10% change in results up to 3500 ng/mL.

Product availability may vary from country to country and is subject to local regulatory requirements.

A
vs contemporary troponin
B
Siemens Healthineers Atellica IM High-Sensitivity Troponin (TnIH) IFU 11200498, Rev. 10, 2024-09
C
Data on File